JP2004527469A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527469A5
JP2004527469A5 JP2002549711A JP2002549711A JP2004527469A5 JP 2004527469 A5 JP2004527469 A5 JP 2004527469A5 JP 2002549711 A JP2002549711 A JP 2002549711A JP 2002549711 A JP2002549711 A JP 2002549711A JP 2004527469 A5 JP2004527469 A5 JP 2004527469A5
Authority
JP
Japan
Prior art keywords
endothelial cells
substances
tumor
growth
prevented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002549711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527469A6 (ja
JP2004527469A (ja
JP4181874B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AT2001/000387 external-priority patent/WO2002048180A2/de
Publication of JP2004527469A publication Critical patent/JP2004527469A/ja
Publication of JP2004527469A6 publication Critical patent/JP2004527469A6/ja
Publication of JP2004527469A5 publication Critical patent/JP2004527469A5/ja
Application granted granted Critical
Publication of JP4181874B2 publication Critical patent/JP4181874B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002549711A 2000-12-12 2001-12-07 ペプチドおよび/またはタンパク質、並びにその治療用および/または予防用医薬成分を調製するための使用 Expired - Fee Related JP4181874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT20632000 2000-12-12
ATA2063/2000 2000-12-12
PCT/AT2001/000387 WO2002048180A2 (de) 2000-12-12 2001-12-07 Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels

Publications (4)

Publication Number Publication Date
JP2004527469A JP2004527469A (ja) 2004-09-09
JP2004527469A6 JP2004527469A6 (ja) 2005-02-03
JP2004527469A5 true JP2004527469A5 (cg-RX-API-DMAC7.html) 2005-04-14
JP4181874B2 JP4181874B2 (ja) 2008-11-19

Family

ID=3689750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002549711A Expired - Fee Related JP4181874B2 (ja) 2000-12-12 2001-12-07 ペプチドおよび/またはタンパク質、並びにその治療用および/または予防用医薬成分を調製するための使用

Country Status (30)

Country Link
US (4) US7271144B2 (cg-RX-API-DMAC7.html)
EP (2) EP1586586B1 (cg-RX-API-DMAC7.html)
JP (1) JP4181874B2 (cg-RX-API-DMAC7.html)
KR (1) KR100864069B1 (cg-RX-API-DMAC7.html)
CN (2) CN1518558B (cg-RX-API-DMAC7.html)
AT (2) ATE425184T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002221316A1 (cg-RX-API-DMAC7.html)
BG (1) BG107891A (cg-RX-API-DMAC7.html)
BR (1) BR0116122A (cg-RX-API-DMAC7.html)
CA (1) CA2430972C (cg-RX-API-DMAC7.html)
CY (2) CY1106108T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031630A3 (cg-RX-API-DMAC7.html)
DE (2) DE50110182D1 (cg-RX-API-DMAC7.html)
DK (2) DK1586586T3 (cg-RX-API-DMAC7.html)
EA (1) EA005576B1 (cg-RX-API-DMAC7.html)
EE (1) EE200300283A (cg-RX-API-DMAC7.html)
ES (2) ES2323963T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030564A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0401536A3 (cg-RX-API-DMAC7.html)
IL (2) IL156360A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03005218A (cg-RX-API-DMAC7.html)
NO (1) NO330767B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ550619A (cg-RX-API-DMAC7.html)
PL (2) PL209419B1 (cg-RX-API-DMAC7.html)
PT (2) PT1586586E (cg-RX-API-DMAC7.html)
SI (2) SI1586586T1 (cg-RX-API-DMAC7.html)
SK (1) SK7062003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002048180A2 (cg-RX-API-DMAC7.html)
YU (1) YU53803A (cg-RX-API-DMAC7.html)
ZA (1) ZA200304545B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1518558B (zh) 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
PT1691827E (pt) * 2004-06-25 2009-11-23 Fibrex Medical Res & Dev Gmbh Utilização de péptidos derivados da cadeia b beta de fibrinogénio humano para o tratamento do choque
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
US7799758B2 (en) * 2006-02-23 2010-09-21 Ikaria Development Subsidiary Two, LLC Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
DK1987063T3 (da) * 2006-02-23 2010-01-04 Fibrex Medical Res & Dev Gmbh Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
FR2900657B1 (fr) 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009038729A2 (en) 2007-09-17 2009-03-26 Regenerx Biopharmaceuticals, Inc. Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
JP5410997B2 (ja) * 2008-01-31 2014-02-05 則行 川村 うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2017210539A1 (en) 2016-06-02 2017-12-07 University Of Maryland, Baltimore Compositions for inhibiting fibrin-vldl receptor-dependent inflammation and methods of treatment
EP3912679A1 (en) * 2020-05-19 2021-11-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Bbeta-15-42 for the treatment of viral endothelitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) * 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
CN1518558B (zh) 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
US7201763B2 (en) * 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Similar Documents

Publication Publication Date Title
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
HUP0102039A2 (hu) Albuminnal stabilizált paclitaxel alkalmazása tömör tumorok kezelésére szolgáló gyógyszerkészítmények előállítására, és a kapott gyógyszerkészítmények
AR046485A1 (es) Sistema de administracion para drogas y terapia celular
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
JP2008526749A5 (cg-RX-API-DMAC7.html)
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
EA200602137A1 (ru) Гидрогелевые препараты интерферона
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
WO2009106819A3 (en) Biological materials and uses thereof
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
Prajapati et al. Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
JP2004002429A5 (cg-RX-API-DMAC7.html)
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
JP2002503687A5 (cg-RX-API-DMAC7.html)
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
EE04966B1 (et) (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks